01.002 RWE APR 2022 HB D 14-04-202

Real world evidence shows that COVID-19 impacts glycated hemoglobin level

  • In this study, data were collected from the COVID-19 data registry developed by a Cleveland clinic, including records of 81,093 COVID-19-positive patients and a control of 153,034 COVID-19-negative patients between March 2020 to May 2021
  • A retrospective analysis of electronic health records (EHR) was performed to determine the impact of COVID-19 on HbA1c levels
  • The study demonstrated an increase in HbA1c (0.06%) in COVID-19-positive patients, while COVID-19-negative patients showed nil or slight increase in HbA1c (0.02%). Between pre and post-COVID-19 testing, a 0.08% HbA1c increase was observed in COVID-19-positive patients compared to COVID-19-negative patients
  • The authors identified a significant positive association in COVID-19-positive patients between pre-COVID-19 HbA1c level and COVID-19-induced severity factors such as hospitalization time, assisted breathing, and ICU admissions
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at